PURPOSE: We evaluated the risk of death from Alzheimer disease (AD) in men with prostate cancer undergoing treatment with or without a luteinizing-hormone releasing hormone (LHRH) agonist. METHODS: Between 1997 and 2007, 6,647 men were treated with brachytherapy for prostate cancer with (N = 1,700) or without (N = 4,947) LHRH agonist therapy. Competing risks multivariable regression was performed to assess whether the use of a LHRH agonist was associated with the risk of death from AD adjusting for the presence of mild AD and age at presentation and known prostate cancer prognostic factors. RESULTS: After a median follow-up of 4.1 years, 1.2% (81/6,647) of the study cohort died from AD accounting for 16% (81/506) of all observed mortality. There was a significant reduction in the risk of death from AD in men who were treated with a LHRH agonist for a median of 4.0 months as compared with those who were not [adjusted hazard ratio: 0.45 (95% confidence interval, 0.25-0.83); P = 0.01]. CONCLUSIONS: LHRH agonist use as compared with no use in men with prostate cancer was associated with a decreased risk of death from AD.
PURPOSE: We evaluated the risk of death from Alzheimer disease (AD) in men with prostate cancer undergoing treatment with or without a luteinizing-hormone releasing hormone (LHRH) agonist. METHODS: Between 1997 and 2007, 6,647 men were treated with brachytherapy for prostate cancer with (N = 1,700) or without (N = 4,947) LHRH agonist therapy. Competing risks multivariable regression was performed to assess whether the use of a LHRH agonist was associated with the risk of death from AD adjusting for the presence of mild AD and age at presentation and known prostate cancer prognostic factors. RESULTS: After a median follow-up of 4.1 years, 1.2% (81/6,647) of the study cohort died from AD accounting for 16% (81/506) of all observed mortality. There was a significant reduction in the risk of death from AD in men who were treated with a LHRH agonist for a median of 4.0 months as compared with those who were not [adjusted hazard ratio: 0.45 (95% confidence interval, 0.25-0.83); P = 0.01]. CONCLUSIONS:LHRH agonist use as compared with no use in men with prostate cancer was associated with a decreased risk of death from AD.
Authors: Kevin T Nead; Greg Gaskin; Cariad Chester; Samuel Swisher-McClure; Joel T Dudley; Nicholas J Leeper; Nigam H Shah Journal: J Clin Oncol Date: 2016-06-13 Impact factor: 44.544
Authors: Syed Nuruddin; Gry Helen Enger Syverstad; Sveinung Lillehaug; Trygve B Leergaard; Lars N G Nilsson; Erik Ropstad; Anette Krogenæs; Ira Ronit Hebold Haraldsen; Reidun Torp Journal: PLoS One Date: 2014-08-04 Impact factor: 3.240
Authors: Kevin T Nead; Greg Gaskin; Cariad Chester; Samuel Swisher-McClure; Joel T Dudley; Nicholas J Leeper; Nigam H Shah Journal: Sci Rep Date: 2016-10-18 Impact factor: 4.379